Mobile

A trial comparing efficacy and safety of semaglutide once-weekly versus placebo as add-on to basal insulin alone or basal insulin in combination with metformin in subjects with type 2 diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1149-3738

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate superiority of once-weekly dosing of two dose levels (0.5 mg and 1.0 mg) of semaglutide versus placebo on glycaemic control in subjects with type 2 diabetes mellitus on basal insulin.

Critère d'inclusion

  • Diabetes Mellitus, Type 2

Liens